Your browser is no longer supported. Please, upgrade your browser.
Settings
GNFT Genfit SA daily Stock Chart
GNFT [NASD]
Genfit SA
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand38.86M Perf Week-1.84%
Market Cap186.13M Forward P/E- EPS next Y- Insider Trans- Shs Float36.89M Perf Month7.16%
Income- PEG- EPS next Q- Inst Own0.42% Short Float0.15% Perf Quarter-4.20%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.54 Perf Half Y-12.11%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-68.55%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.63 - 22.48 Perf YTD-75.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.75% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.82% ATR0.38
Employees203 Current Ratio- Sales Q/Q-0.10% Oper. Margin- RSI (14)57.04 Volatility7.90% 7.03%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.03 Prev Close4.79
ShortableYes LT Debt/Eq- EarningsSep 30 AMC Payout- Avg Volume105.95K Price5.00
Recom- SMA2016.09% SMA5012.58% SMA200-43.37% Volume54,128 Change4.44%
Jul-23-20Upgrade Stifel Hold → Buy
Jun-25-20Initiated BofA/Merrill Underperform $7
May-13-20Downgrade Kepler Buy → Reduce
May-12-20Downgrade H.C. Wainwright Buy → Neutral $46 → $11
May-12-20Downgrade Barclays Overweight → Equal Weight $55 → $14
Oct-29-19Reiterated B. Riley FBR Buy $52 → $43
Jun-25-19Initiated Stifel Hold
Apr-24-19Initiated SVB Leerink Outperform $58
Apr-22-19Initiated Barclays Overweight
Nov-23-20 02:15AM  
Nov-16-20 04:10PM  
02:30AM  
Sep-30-20 04:05PM  
02:30PM  
Sep-28-20 02:00AM  
Sep-25-20 07:37AM  
Sep-24-20 04:10PM  
Sep-22-20 04:10PM  
Sep-02-20 11:20AM  
Aug-26-20 04:10PM  
Aug-05-20 07:35AM  
02:30AM  
Jul-23-20 11:02AM  
Jul-22-20 04:05PM  
Jul-10-20 04:05PM  
Jun-30-20 10:29AM  
Jun-29-20 04:05PM  
Jun-15-20 05:19PM  
Jun-10-20 08:36AM  
May-26-20 01:19PM  
May-14-20 05:31PM  
May-12-20 02:20PM  
01:17PM  
11:03AM  
08:06AM  
04:39AM  
04:35AM  
May-11-20 05:52PM  
Apr-17-20 08:43AM  
Apr-11-20 02:32AM  
Mar-30-20 06:06PM  
Mar-04-20 04:26PM  
Mar-03-20 02:20PM  
Mar-02-20 05:35PM  
10:25AM  
Feb-26-20 03:06PM  
Feb-25-20 03:10PM  
11:00AM  
Feb-24-20 04:45PM  
02:23PM  
Feb-21-20 11:57AM  
Feb-17-20 05:35AM  
Jan-08-20 07:37AM  
Jan-02-20 09:08AM  
Dec-22-19 05:32PM  
Dec-10-19 03:36PM  
Nov-26-19 08:06AM  
Nov-18-19 02:57AM  
Nov-09-19 02:58PM  
Oct-03-19 09:29AM  
Aug-19-19 02:45PM  
Aug-13-19 02:10AM  
Jul-08-19 04:32AM  
Jun-29-19 06:18PM  
Jun-25-19 07:15AM  
Jun-24-19 04:31PM  
Jun-17-19 01:50PM  
May-09-19 02:00PM  
May-02-19 03:43PM  
May-01-19 11:12AM  
Apr-30-19 10:24AM  
Apr-25-19 10:11AM  
Apr-24-19 09:04AM  
Apr-15-19 04:26PM  
Apr-07-19 02:00PM  
Apr-02-19 06:34PM  
Mar-27-19 06:13PM  
Mar-24-19 05:16PM  
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.